Recent Searches
Chris is an EY-Parthenon partner who advises clients on complex transactions across the full life sciences deal lifecycle. He leads transaction programs on both the buy and sell side, with in-depth project management office (PMO) leadership, pre-commercial acquisitions, complex separations, value creation, and separation and integration planning and execution. His primary sector focus is life sciences, including biopharma and MedTech.
Chris progressed through the EY Strategy and Transactions practice, including working in Operational Transaction Services. He holds an MBA from the University of Pittsburgh (Katz Graduate School of Business) and a BA from Pennsylvania State University.
Chris is shaping the future with confidence by helping life sciences clients navigate complex, high-stakes transactions with clarity and discipline. He leads transaction programs across the full deal lifecycle to guide organizations through pivotal moments of change.
By applying rigorous planning, a strong focus on value creation and preservation, and cross-functional alignment, he empowers clients to move through uncertainty with greater confidence and speed. His work across acquisitions and divestitures helps companies realize deal value while building more agile and sustainable operating models.
Through this approach, Chris enables teams to deliver on bold ambitions, strengthen organizational capability and accelerate progress toward long-term, transformative outcomes.
